ストックスクリーナーアプリを入手
107.00
0.36%
0.38
アフターアワーズ：
106.05
-0.95
-0.89%
前日終値:
$106.62
開ける：
$107.68
24時間の取引高:
2.35M
Relative Volume:
0.63
時価総額：
$23.19B
収益：
$819.56M
当期純損益:
$-1.18B
株価収益率:
-18.63
EPS:
-5.7434
ネットキャッシュフロー:
$-951.64M
1週間 パフォーマンス:
+3.42%
1か月 パフォーマンス:
+0.91%
6か月 パフォーマンス:
-38.52%
1年 パフォーマンス:
+9.61%
1日の値動き範囲:
$106.01
$109.19
1週間の範囲:
$101.67
$109.19
52週間の値動き範囲:
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
Compare INSM vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
107.00 | 23.11B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
498.01 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
624.72 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
909.50 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.67 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
187.51 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Raymond James | Outperform |
| 2026-03-30 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | 再開されました | Jefferies | Buy |
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2026-01-23 | 開始されました | Roth Capital | Buy |
| 2025-12-19 | 再開されました | Truist | Buy |
| 2025-12-04 | 開始されました | Rothschild & Co Redburn | Buy |
| 2025-10-28 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-08-20 | 開始されました | William Blair | Outperform |
| 2025-08-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 開始されました | Jefferies | Buy |
| 2025-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-04-23 | 開始されました | Truist | Buy |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-07-26 | 開始されました | Guggenheim | Buy |
| 2022-12-09 | 開始されました | Mizuho | Buy |
| 2022-12-07 | 開始されました | Barclays | Overweight |
| 2022-11-18 | 開始されました | BofA Securities | Buy |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2021-12-06 | 開始されました | JP Morgan | Overweight |
| 2021-10-19 | 再開されました | Monness Crespi & Hardt | Buy |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2021-10-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-10-12 | 再開されました | Stifel | Buy |
| 2019-09-03 | 開始されました | Goldman | Buy |
| 2019-04-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-15 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | アップグレード | Goldman | Neutral → Buy |
| 2019-01-02 | 開始されました | Canaccord Genuity | Buy |
| 2018-08-06 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | 開始されました | Goldman | Neutral |
| 2018-04-23 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | 開始されました | Morgan Stanley | Overweight |
| 2018-01-18 | 開始されました | Credit Suisse | Neutral |
| 2017-09-05 | 繰り返されました | Evercore ISI | Outperform |
| 2017-08-17 | 開始されました | Evercore ISI | Outperform |
| 2017-07-11 | 開始されました | Robert W. Baird | Outperform |
| 2016-03-15 | 開始されました | Stifel | Buy |
| 2015-11-09 | ダウングレード | UBS | Buy → Neutral |
| 2015-10-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-06-09 | 開始されました | Citigroup | Neutral |
| 2014-03-26 | 繰り返されました | HC Wainwright | Buy |
すべてを表示
Insmed Inc (INSM) 最新ニュース
Here’s Why TimesSquare Mid Cap Growth Strategy Added Insmed (INSM) - Yahoo Finance
Analysts Expect Breakeven For Insmed Incorporated (NASDAQ:INSM) Before Long - Moomoo
INSMInsmed Inc Options - Finviz
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
Insmed Incorporated(NasdaqGS: INSM) dropped from Russell 2500 Growth Benchmark - marketscreener.com
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Insmed Incorporated(NasdaqGS:INSM) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Insmed Incorporated(NasdaqGS: INSM) dropped from Russell 3000 Value Benchmark - marketscreener.com
Insmed Incorporated(NasdaqGS: INSM) dropped from Russell Midcap Value Benchmark - marketscreener.com
Mizuho Maintains an Outperform Rating on Insmed Incorporated (INSM) - Yahoo Finance
INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study - Stocktwits
Insmed Inc (INSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Insmed Insider Sold Shares Worth $2,210,763, According to a Recent SEC Filing - marketscreener.com
INSMED (INSM) CEO Lewis exercises options and sells 21,398 shares under 10b5-1 plan - Stock Titan
Price to earnings forward of Insmed Incorporated – NASDAQ:INSM - TradingView
Form 144 INSMED INC For: 25 June - Investing.com UK
Form 144 INSMED INC For: 25 June By Investing.com - Investing.com Nigeria
Insmed Incorporated Actuals & Estimates (NASDAQ:INSM) - TradingView
Insmed Incorporated Actuals & Estimates (BX:IM8N) - TradingView
William Lewis files Form 144 — Insmed (NASDAQ: INSM) reports recent share dispositions - Stock Titan
Insmed | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Enterprise value to EBITDA forward of Insmed Incorporated – NASDAQ:INSM - TradingView
Enterprise value to EBIT forward of Insmed Incorporated – SWB:IM8N - TradingView
Price to book forward of Insmed Incorporated – SWB:IM8N - TradingView
Enterprise value to revenue forward of Insmed Incorporated – SWB:IM8N - TradingView
IM8N Forecast — Price Target — Prediction for 2027 - TradingView
Insmed names Butera SVP, general manager, global respiratory - ROI-NJ
Enterprise value to EBITDA forward of Insmed Incorporated – SWB:IM8N - TradingView
Non-Cystic Fibrosis Bronchiectasis Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring, Chiesi Farmace - Barchart.com
EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis - Yahoo Finance
Form 4 Insmed Inc For: 24 June By Investing.com - Investing.com Australia
Insmed chief legal officer Michael Smith sells $173,050 in stock By Investing.com - Investing.com South Africa
Insmed chief legal officer Michael Smith sells $173,050 in stock - Investing.com
Insider Sell Alert: Michael Smith Sells Shares of Insmed Inc (IN - GuruFocus
Insmed (NASDAQ: INSM) awards RSUs and stock options to SVP - Stock Titan
Insmed (INSM) SVP Samuele Butera files Form 3 showing no trades - Stock Titan
INSMED Inc (NASDAQ: INSM) CLO sells 1,806 shares under 10b5-1 plan - Stock Titan
Insmed Incorporated Announces Appointment of Samuele Butera as Senior Vice President, Global Respiratory and Member of Executive Committee, Effective June 23, 2026 - marketscreener.com
Press Release: Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory - Moomoo
Form 144 INSMED INC For: 22 June By Investing.com - Investing.com Australia
INSM Maintained by Evercore ISI Group -- Price Target Lowered to $160 - GuruFocus
Insmed taps Johnson & Johnson veteran to lead its respiratory push - Stock Titan
Form 144 INSMED INC For: 22 June - Investing.com UK
Should Insmed’s (INSM) NASDAQ-100 Exit and TPIP Focus Require Action From Investors? - Yahoo Finance
Michael Smith files Form 144 listing multiple INSM share sales (INSM) - Stock Titan
Is Insmed (INSM) One of the Most Promising Healthcare Stocks After Cantor Fitzgerald’s Target Raise? - Yahoo Finance
What's Driving Insmed's Recent Volatility - Kavout | AI
3 US Pharmaceutical Stocks With Cash Flow And Pricing Risk - Sahm
Insmed Stockanalyst coverage and sector comparison at week’s end - Ad-hoc-news.de
Insmed Inc (MIL:1INSM) Stock Price, Trades & News - GuruFocus
InvestingPro’s Fair Value spotted Insmed’s 44% drop before it happened By Investing.com - Investing.com
Insmed Inc (INSM) 財務データ
収益
当期純利益
現金流量
EPS
0.93%
0.52%
大文字化:
|
ボリューム (24 時間):